Financial Performance - Revenue for the year ended December 31, 2024, was RMB 199,342,000, representing an increase of 5.2% from RMB 189,384,000 in 2023[4] - Gross profit for the same period was RMB 71,407,000, slightly down from RMB 71,493,000 in 2023, indicating a marginal decrease of 0.12%[4] - The company reported a net loss of RMB 63,263,000 for the year, compared to a net loss of RMB 37,779,000 in 2023, reflecting an increase in losses of 67.5%[4] - The basic and diluted loss per share for the year was RMB 0.1111, compared to RMB 0.0675 in 2023, indicating a worsening of 64.4%[4] - The adjusted loss before tax was RMB (15,330) thousand, a 33.9% improvement from RMB (23,200) thousand in 2023[53] - The adjusted net loss for the year was RMB (18,762) thousand, a 27.8% improvement from RMB (25,969) thousand in 2023[53] - The group reported a pre-tax loss of RMB 65,257,000 for 2024, compared to a pre-tax loss of RMB 35,010,000 in 2023, indicating a significant increase in losses[33] Assets and Liabilities - Total current assets increased to RMB 90,434,000 from RMB 79,616,000, marking an increase of 13.4%[5] - Total non-current assets decreased to RMB 159,489,000 from RMB 193,983,000, a decline of 17.8%[5] - The company's total liabilities increased to RMB 154,405,000 from RMB 141,009,000, an increase of 9.5%[6] - The equity attributable to the owners of the parent company decreased to RMB 104,134,000 from RMB 138,115,000, a decline of 24.6%[6] - As of December 31, 2024, cash and bank balances were approximately RMB 289 million, down from RMB 398 million in 2023, primarily due to costs incurred for acquiring distribution rights for collagen injection products[79] - The total debt as of December 31, 2024, was approximately RMB 1,544 million, with a debt-to-equity ratio of approximately 161.7%, up from 106.3% in 2023[87] Revenue Segmentation - Medical beauty services generated RMB 142,097 thousand in revenue for 2024, down from RMB 174,910 thousand in 2023, indicating a decline of about 18.8%[25] - Medical beauty device products saw a significant increase in revenue, rising to RMB 57,216 thousand in 2024 from RMB 14,474 thousand in 2023, marking a growth of approximately 295.5%[25] - The consulting services segment contributed RMB 29 thousand in revenue for 2024, compared to no revenue reported in 2023[25] - Revenue from surgical services fell to approximately RMB 4.1 million in 2024, a decline of 41.3% from RMB 6.9 million in 2023, attributed to changing consumer preferences[63] - Revenue from medical beauty device sales surged by 295.3% to approximately RMB 57.2 million in 2024, compared to RMB 14.5 million in 2023[61] Expenses and Costs - Research and development expenses decreased to RMB 717,000 from RMB 1,602,000, a reduction of 55.2%[4] - Capital expenditures for the year 2024 totaled RMB 43,650 thousand, which included investments in property, plant, equipment, and intangible assets[23] - The company reported a total employee cost of approximately RMB 66.7 million for the year, a decrease of RMB 2.1 million compared to RMB 68.8 million in 2023, representing 33.5% of total revenue for 2024[96] - Administrative expenses in 2024 were approximately RMB 418 million, an increase of RMB 17 million from RMB 401 million in 2023, mainly due to increased share-based payment expenses[75] - Sales and distribution expenses in 2024 were approximately RMB 477 million, a decrease of about 8.8% from RMB 523 million in 2023, attributed to restructuring the marketing system[74] Strategic Plans and Developments - The company plans to apply the new and revised International Financial Reporting Standards (IFRS) upon their effective date, which includes IFRS 18, IFRS 19, and amendments to IFRS 9 and IFRS 7[12][13][14][17]. - The company plans to enhance non-surgical service capacity by introducing the latest medical beauty technologies and increasing investment in minimally invasive and skin beauty services[44] - The company plans to establish a medical beauty training center in Hainan, enhancing the professional level of doctors and improving service quality[47] - The company aims to expand its sales channels through digital marketing and partnerships with suppliers and distributors to enhance operational efficiency[48] - The company is considering strategic acquisitions of suitable medical beauty institutions or medical device companies to strengthen its market position[50] Compliance and Governance - The audit committee has reviewed and approved the annual performance of the group, ensuring compliance with applicable accounting standards and regulations[119] - The company has acknowledged a compliance oversight regarding the announcement of supply agreements and service agreements, committing to enhance training and internal controls to prevent future occurrences[109] - The company has established a competitive compensation structure for its medical staff, with annual performance reviews influencing salary and bonus determinations[98] Market Trends - The medical beauty industry is shifting from niche to mass consumption, driven by rising consumer awareness and the popularity of non-surgical procedures[112] - The company plans to focus on developing non-surgical medical beauty services and increase investment in technology and research[112]
瑞丽医美(02135) - 2024 - 年度业绩